PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
Abstract: we have performed the first-ever comparative pharmacoeconomic analysis in a Russian context of bendamustine in the first line of therapy of a multiple myeloma for for patients more senior 65 years old with clinical manifestations of a polineuropathy, which autological transplantation of st...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2015-03-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/64 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849394401453801472 |
|---|---|
| author | A. S. Kolbin I. A. Vilum Yu. E. Balykina M. A. Proskurin |
| author_facet | A. S. Kolbin I. A. Vilum Yu. E. Balykina M. A. Proskurin |
| author_sort | A. S. Kolbin |
| collection | DOAJ |
| description | Abstract: we have performed the first-ever comparative pharmacoeconomic analysis in a Russian context of bendamustine in the first line of therapy of a multiple myeloma for for patients more senior 65 years old with clinical manifestations of a polineuropathy, which autological transplantation of stem cells isn’t shown. Research was conducted from a position of the state health system by means of mathematical modeling. Markov modeling and the sensitivity analysis were used. For primary patients who aren’t candidates for transplantation the following regimes of treatment were compared of: bendamustine + prednisone; melphalan + prednisone; bortezomibe + dexamethasone. The results show that the use of bendamustine in the first line of therapy of a multiple myeloma for elderly patients with the phenomena of a polyneuropathy is economically expedient from the point of view of a ratio of cost and efficiency. |
| format | Article |
| id | doaj-art-265df2a3eb9a4ff886ac9afedb0c4b7d |
| institution | Kabale University |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2015-03-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-265df2a3eb9a4ff886ac9afedb0c4b7d2025-08-20T03:40:00ZrusIRBIS LLCФармакоэкономика2070-49092070-49332015-03-017261258PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLDA. S. Kolbin0I. A. Vilum1Yu. E. Balykina2M. A. Proskurin3First Pavlov State Medical University of St. Peterburg; Saint Petersburg State University, St. Petersburg, RussiaNational Medical and Surgical Center of the N.I. Pirogov, St. PeterburgSaint Petersburg State University, St. Petersburg, RussiaSaint Petersburg State University, St. Petersburg, RussiaAbstract: we have performed the first-ever comparative pharmacoeconomic analysis in a Russian context of bendamustine in the first line of therapy of a multiple myeloma for for patients more senior 65 years old with clinical manifestations of a polineuropathy, which autological transplantation of stem cells isn’t shown. Research was conducted from a position of the state health system by means of mathematical modeling. Markov modeling and the sensitivity analysis were used. For primary patients who aren’t candidates for transplantation the following regimes of treatment were compared of: bendamustine + prednisone; melphalan + prednisone; bortezomibe + dexamethasone. The results show that the use of bendamustine in the first line of therapy of a multiple myeloma for elderly patients with the phenomena of a polyneuropathy is economically expedient from the point of view of a ratio of cost and efficiency.https://www.pharmacoeconomics.ru/jour/article/view/64multiple myelomabendamustinepharmacoeconomics |
| spellingShingle | A. S. Kolbin I. A. Vilum Yu. E. Balykina M. A. Proskurin PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Фармакоэкономика multiple myeloma bendamustine pharmacoeconomics |
| title | PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD |
| title_full | PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD |
| title_fullStr | PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD |
| title_full_unstemmed | PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD |
| title_short | PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD |
| title_sort | pharmacoeconomic analysis of the use of ribomustin r in therapy of the first line of a multiple myeloma for patients more senior 65 years old |
| topic | multiple myeloma bendamustine pharmacoeconomics |
| url | https://www.pharmacoeconomics.ru/jour/article/view/64 |
| work_keys_str_mv | AT askolbin pharmacoeconomicanalysisoftheuseofribomustinintherapyofthefirstlineofamultiplemyelomaforpatientsmoresenior65yearsold AT iavilum pharmacoeconomicanalysisoftheuseofribomustinintherapyofthefirstlineofamultiplemyelomaforpatientsmoresenior65yearsold AT yuebalykina pharmacoeconomicanalysisoftheuseofribomustinintherapyofthefirstlineofamultiplemyelomaforpatientsmoresenior65yearsold AT maproskurin pharmacoeconomicanalysisoftheuseofribomustinintherapyofthefirstlineofamultiplemyelomaforpatientsmoresenior65yearsold |